Result of Retail Offer

CRISM Therapeutics Corporation

28 May 2026

 

This Announcement does not constitute a prospectus or offering memorandum or an offer in respect of any securities and is not intended to provide the basis for any investment decision in respect of CRISM Therapeutics Corporation or other evaluation of any securities of CRISM Therapeutics Corporation or any other entity and should not be considered as a recommendation that any investor should subscribe for or purchase any such securities.

This Announcement contains inside information as defined in Article 7 of the UK version of the Market Abuse Regulation (EU No.596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended by the European Union (Withdrawal) Act 2020 ("UK MAR"). In addition, market soundings (as defined in UK MAR) were taken in respect of certain of the matters contained in this Announcement, with the result that certain persons became aware of such inside information, as permitted by UK MAR. Upon the publication of this Announcement, this inside information is now considered to be in the public domain and such persons shall therefore cease to be in possession of inside information.

28 May 2026

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

Result of Retail Offer

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce that the Retail Offer which launched on 26 May 2026 has successfully completed and closed today at 11:00 a.m.

The Retail Offer was significantly oversubscribed and in the light of the oversubscription, the Directors have elected to exercise their right to increase the size of the Retail Offer to £245,000 through the issue of 2,450,000 Ordinary Shares, subject to approval by Shareholders of the Resolutions at the Company's General Meeting to be held on 15 June 2026.

The proceeds of the Retail Offer, together with the Placing announced on 26 May 2026, will provide the Company with the finance required to help secure significant grant funding, subject to confirmation, progress its Phase 2 open-label clinical trial of irinotecan-ChemoSeed for the treatment of glioblastoma, and support the continued development of docetaxel-ChemoSeed for prostate cancer.

Completion of the Retail Offer and issue of the Retail Offer Shares is conditional, inter alia, upon approval of the Shareholders at the General Meeting to be held on 15 June 2026.

Capitalised terms not defined shall have the same meaning as given to them in the Circular, posted to Shareholders on 27 May 2026.

-Ends-

Enquiries:

Company	Nomad and Broker	Financial PR
CRISM Therapeutics Corporation	S.P. Angel Corporate Finance LLP	Burson Buchanan
Andrew Webb, Executive Chairman Chris McConville, CSO	David Hignell Vadim Alexandre Adam Cowl	Henry Harrison Topham Jamie Hooper [e-mail]
via Burson Buchanan	[phone]	[phone]

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

For more information please visit: https://www.crismtherapeutics.com/

The Company's LEI is 213800XFW6MKVCHHPW88.

 

END